The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies

被引:170
作者
Nahimana, Aimable [1 ]
Attinger, Antoine [2 ]
Aubry, Dominique [1 ]
Greaney, Peter [2 ]
Ireson, Christopher [2 ]
Thougaard, Annemette V. [3 ]
Tjornelund, Jette [3 ]
Dawson, Keith M. [2 ]
Dupuis, Marc [2 ]
Duchosal, Michel A. [1 ]
机构
[1] Univ Lausanne Hosp, Serv Hematol, Lausanne, Switzerland
[2] TopoTarget Switzerland, Lausanne, Switzerland
[3] TopoTarget Denmark, Copenhagen, Denmark
关键词
NICOTINAMIDE ADENINE-DINUCLEOTIDE; MAMMALIAN-CELLS; COLORECTAL-CANCER; DNA-DAMAGE; DEPLETION; APOPTOSIS; FK866; AUTOPHAGY; DEATH; CASCADE;
D O I
10.1182/blood-2008-08-173369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
APO866 inhibits nicotinamide phosphoribosyltransferase (NMPRTase), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Intracellular NAD is essential for cell survival, and NAD depletion resulting from APO866 treatment elicits tumor cell death. Here, we determine the in vitro and in vivo sensitivities of hematologic cancer cells to APO866 using a panel of cell lines (n = 45) and primary cells (n = 32). Most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low concentrations of APO866 as measured in cytotoxicity and clonogenic assays. Treatment with APO866 decreased intracellular NAD and adenosine triphosphate (ATP) at 24 hours and 48 to 72 hours, respectively. The NAD depletion led to cell death. At 96 hours, APO866-mediated cell death occurred in a caspase-independent mode, and was associated with mitochondrial dysfunction and autophagy. Further, in vivo administration of APO866 as a single agent prevented and abrogated tumor growth in animal models of human AML, lymphoblastic lymphoma, and leukemia without significant toxicity to the animals. The results support the potential of APO866 for treating hematologic malignancies. (Blood. 2009; 113:3276-3286)
引用
收藏
页码:3276 / 3286
页数:11
相关论文
共 28 条
[1]   Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition [J].
Alano, CC ;
Ying, WH ;
Swanson, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (18) :18895-18902
[2]   POLY(ADP-RIBOSE) BIOSYNTHESIS AND SUICIDAL NAD+ DEPLETION FOLLOWING CARCINOGEN EXPOSURE OF MAMMALIAN-CELLS [J].
ALVAREZGONZALEZ, R ;
EICHENBERGER, R ;
ALTHAUS, FR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 138 (03) :1051-1057
[3]   Improved long-distance polymerase chain reaction for the detection of t(8;14)(q24;q32) in Burkitt's lymphomas [J].
Basso, K ;
Frascella, E ;
Zanesco, L ;
Rosolen, A .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (05) :1479-1485
[4]   NAD depletion by FK866 induces autophagy [J].
Billington, Richard A. ;
Genazzani, Armando A. ;
Travelli, Ctistina ;
Condorelli, Fabrizio .
AUTOPHAGY, 2008, 4 (03) :385-387
[5]   Characterization of NAD uptake in mammalian cells [J].
Billington, Richard A. ;
Travelli, Cristina ;
Ercolano, Emanuela ;
Galli, Ubaldina ;
Roman, Cintia Blasi ;
Grolla, Ambra A. ;
Canonico, Pier Luigi ;
Condorelli, Fabrizio ;
Genazzani, Armando A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (10) :6367-6374
[6]   Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase/Visfatin Enzymatic Activity Identifies a New Inflammatory Pathway Linked to NAD [J].
Busso, Nathalie ;
Karababa, Mahir ;
Nobile, Massimo ;
Rolaz, Aline ;
Van Gool, Frederic ;
Galli, Mara ;
Leo, Oberdan ;
So, Alexander ;
De Smedt, Thibaut .
PLOS ONE, 2008, 3 (05)
[7]   Assay of human stem cells by repopulation of NOD/SCID mice [J].
Dick, JE ;
Bhatia, M ;
Gan, O ;
Kapp, U ;
Wang, JCY .
STEM CELLS, 1997, 15 :199-203
[8]  
Drevs J, 2003, ANTICANCER RES, V23, P4853
[9]   Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress [J].
Du, LN ;
Zhang, XP ;
Han, YY ;
Burke, NA ;
Kochanek, PM ;
Watkins, SC ;
Graham, SH ;
Carcillo, JA ;
Szabó, C ;
Clark, RSB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (20) :18426-18433
[10]   A Fas agonist induces high levels of apoptosis in haematological malignancies [J].
Greaney, P ;
Nahimana, A ;
Lagopoulos, L ;
Etter, AL ;
Aubry, D ;
Attinger, A ;
Beltraminelli, N ;
Huni, B ;
Bassi, I ;
Sordat, B ;
Demotz, S ;
Dupuis, M ;
Duchosal, MA .
LEUKEMIA RESEARCH, 2006, 30 (04) :415-426